Patents by Inventor Andreas von Deimling

Andreas von Deimling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240331864
    Abstract: The present disclosure relates to a computer-implemented method for cancer diagnosis, comprising: a) selectively sequencing polymers of a biological sample according to at least one target gene site by translocating the polymers through nanopores of a nanopore sequencing system, including: (i) analyzing an initial nucleotide sequence of a first polymer of the biological sample while the first polymer is translocating through a nanopore of the nanopore sequencing system to determine whether the initial nucleotide sequence corresponds to the at least one target gene site; and (ii) continuing the sequencing of the first polymer to obtain measurement data of the first polymer only if the initial nucleotide sequence of the first polymer corresponds to the at least one target gene site: b) determining, based on the measurement data, a biological state of a nucleotide sequence of the first polymer corresponding to the at least one target gene site; and c) classifying a cancer using a classification algorithm based o
    Type: Application
    Filed: August 4, 2022
    Publication date: October 3, 2024
    Applicants: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS, UNIVERSITAET HEIDELBERG, OXFORD NANOPORE TECHNOLOGIES PLC
    Inventors: Felix SAHM, Martin SILL, Andreas VON DEIMLING, Stefan PFISTER, David JONES, Areeba PATEL, Helin DOGAN, Matt LOOSE, Alexander PAYNE
  • Publication number: 20180066317
    Abstract: The present invention pertains to methods for classifying tumorous diseases based on their specific genomic DNA methylation profile. The invention provides a method that allows for a classification of a tumor sample obtained from a patient by analysing a multitude, preferably genome wide, collection of CpG positions by comparison to a classification rule derived from a set of methylation data acquired from pre-classified tumor species. The invention is in particular useful for classifying brain tumor samples since brain tumors are characterized by a large variety of distinct tumor species which have different prognostic values and require in the clinic a for each species developed treatment regime.
    Type: Application
    Filed: September 15, 2016
    Publication date: March 8, 2018
    Applicants: Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts, Ruprecht-Karls-Universität Heidelberg
    Inventors: STEFAN PFISTER, ANDREAS VON DEIMLING, DAVID JONES, DAVID CAPPER, VOLKER HOVESTADT, MARTIN SILL, MELANIE BEWERUNGE-HUDLER, MATTHIAS SCHICK
  • Patent number: 9487815
    Abstract: The present invention relates to a method for detecting (D)-2-hydroxyglutarate or (D)-2-hydroxyadipic acid in a sample, the method comprising the steps of: a) contacting a sample with a reagent mixture, wherein said reagent mixture comprises: (i) a solvent, (ii) a dye having an oxidized state and a reduced state, wherein the reduced state can be distinguished from the oxidized state and wherein the dye is initially present in the oxidized state, (iii) an electron transfer agent, (iv) a (D)-2-hydroxyglutarate dehydrogenase enzyme, and (v) a cofactor; and b) detecting (D)-2-hydroxyglutarate or (D)-2-hydroxyadipic acid by measuring the production of the reduced state of the dye. The invention further pertains to a method for diagnosing and/or monitoring a (D)-2-hydroxy-glutarate-associated disease in a subject. Encompassed by the invention is also a method for diagnosing a mutation in an isocitrate dehydrogenase (IDH) gene or in a (D)-2-hydroxyglutarate (D2HG) dehydrogenase enzyme gene in a subject.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: November 8, 2016
    Assignees: DKFZ Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universität Heidelberg
    Inventors: Jörg Balss, Stefan Pusch, Andreas Von Deimling, Wolfgang Buckel
  • Patent number: 9297812
    Abstract: The present invention relates to the field of diagnostic tests and diagnostic tools. Specifically, contemplated is to a method for diagnosing cancer in a sample of a subject suspected to suffer from cancer comprising contacting the sample with an antibody which specifically binds to the epitope characterized by SEQ ID NO 1 on a BRAF polypeptide under conditions which allow for binding of said antibody to the epitope and determining binding of the antibody to the epitope, whereby cancer is diagnosed. Further contemplated are antibodies which specifically bind to the epitope characterized by SEQ ID NO 1 on a BRAF polypeptide and a device or kit comprising such antibodies.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: March 29, 2016
    Assignees: Deutsches Krebsforschungzentrum, Ruprecht-Karl-Universität Heidelberg
    Inventors: Hanswalter Zentgraf, Ulrike Zentgraf, Andreas Von Deimling, David Capper
  • Publication number: 20150044716
    Abstract: The present invention relates to a method for detecting (D)-2-hydroxyglutarate or (D)-2-hydroxyadipic acid in a sample, the method comprising the steps of: a) contacting a sample with a reagent mixture, wherein said reagent mixture comprises: (i) a solvent, (ii) a dye having an oxidized state and a reduced state, wherein the reduced state can be distinguished from the oxidized state and wherein the dye is initially present in the oxidized state, (iii) an electron transfer agent, (iv) a (D)-2-hydroxyglutarate dehydrogenase enzyme, and (v) a cofactor; and b) detecting (D)-2-hydroxyglutarate or (D)-2-hydroxyadipic acid by measuring the production of the reduced state of the dye. The invention further pertains to a method for diagnosing and/or monitoring a (D)-2-hydroxy-glutarate-associated disease in a subject. Encompassed by the invention is also a method for diagnosing a mutation in an isocitrate dehydrogenase (IDH) gene or in a (D)-2-hydroxyglutarate (D2HG) dehydrogenase enzyme gene in a subject.
    Type: Application
    Filed: March 1, 2013
    Publication date: February 12, 2015
    Applicants: DKFZ Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universität Heidelberg
    Inventors: Jörg Balss, Stefan Pusch, Andreas Von Deimling, Wolfgang Buckel
  • Patent number: 8367347
    Abstract: The present invention relates to methods for the diagnosis of a brain tumor and for the estimation of a prognosis for patients having a brain tumor using the presence/absence of a particular IDH1 mutation as a marker.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: February 5, 2013
    Assignee: Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts and Ruprecht-Karls-Univeristat Heidelberg
    Inventors: Christian Hartmann, Andreas von Deimling, Hanswalter Zentgraf, David Capper, Guido Reifenberger, Michael Weller, Wolfgang Wick
  • Publication number: 20100291590
    Abstract: The present invention relates to methods for the diagnosis of a brain tumor and for the estimation of a prognosis for patients having a brain tumor using the presence/absence of a particular IDH1 mutation as a marker.
    Type: Application
    Filed: December 14, 2009
    Publication date: November 18, 2010
    Inventors: Christian Hartmann, Andreas von Deimling, Hanswalter Zentgraf, David Capper, Guido Reifenberger, Michael Weller, Wolfgang Wick